Skip to content

Intrathecal Dexmedetomidine With Bupivacaine, in Patients Undergoing Knee Orthopedic Surgery

The Analgesic Effect of Intrathecal Dexmedetomidine With Bupivacaine, in Patients Undergoing Knee Orthopedic Surgery: A Randomized Double-Blinded Dose-Finding Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07522736
Enrollment
120
Registered
2026-04-13
Start date
2025-03-01
Completion date
2026-08-30
Last updated
2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bupivacaine, Intrathecal Dexmedetomidine, Knee Orthopedic Surgery

Brief summary

This study aims to compare the duration of analgesia (as the primary outcome) and adverse effects (as the secondary outcome) after intrathecal administration of dexmedetomidine with hyperbaric bupivacaine to patients undergoing knee orthopedic surgery.

Detailed description

Intrathecal adjuncts are commonly added to local anesthetic agents, to improve the duration of nerve blocks and postoperative pain relief without increasing the dosage of local anesthetic. Studies have shown that dexmedetomidine (DEX) has a greater potential for enhancing analgesic effects due to its higher specificity for alpha2 adrenoceptors. DEX is commonly used for sedation and as an adjunct to reduce the amount of anesthesia and opioids required during general and regional anesthesia in both adults and children.

Interventions

DRUGDexmedetomidine 4 μg

Patients will receive intrathecal hyperbaric bupivacaine 15 mg, supplemented with dexmedetomidine 4 μg.

Patients will receive intrathecal hyperbaric bupivacaine 15 mg, supplemented with dexmedetomidine 8 μg.

DRUGDexmedetomidine 12 μg

Patients will receive intrathecal hyperbaric bupivacaine 15 mg, supplemented with dexmedetomidine 12 μg.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age from 18 to 65 years. * American Society of Anesthesiologists (ASA) physical status I-II. * Male patients scheduled for knee orthopedic surgery.

Exclusion criteria

* Patients with psychiatric disorders. * History of drug addiction. * Contraindication for regional anesthesia. * History of hypersensitivity to the study drugs. * Previous administration of opioids and/or other central nervous system depressants during current hospital admission.

Design outcomes

Primary

MeasureTime frameDescription
Time to request rescue analgesia24 hours postoperativelyTime to request rescue analgesia will be recorded from the end of surgery to the first dose of morphine administrated

Secondary

MeasureTime frameDescription
Heart rateIn the recovery room (Up to 2 hours)Heart rate will be recorded every two minutes for the first ten minutes and then every five minutes until the end of surgery and then in the recovery room.
Mean arterial blood pressureIn the recovery room (Up to 2 hours)Mean arterial blood pressure will be recorded every two minutes for the first ten minutes and then every five minutes until the end of surgery and then in the recovery room.
Respiratory rateIn the recovery room (Up to 2 hours)Respiratory rate will be recorded every two minutes for the first ten minutes and then every five minutes until the end of surgery and then in the recovery room.
Oxygen saturationIn the recovery room (Up to 2 hours)Oxygen saturation will be recorded every two minutes for the first ten minutes and then every five minutes until the end of surgery and then in the recovery room.

Countries

Egypt

Contacts

CONTACTAhmed A Ismail, MSc
ahmed.ali39348@postgrad.kasralainy.edu.eg00201115746779

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 14, 2026